Gracell Biotech boosts US IPO size to $209m

Jonathan Breen

January 08, 2021 08:30 am

Healthcare medical biopharmaceutical investing stock chart background | Kurhan - stock.adobe.com

Gracell Biotechnologies has raised $209m from its Nasdaq IPO after increasing the size of the float and pricing the deal above the initial marketed range.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Equity IPOs Health and Biotech Equity China Americas Citi Jefferies LLC Asia Greater China Northeast Asia Asia Pacific Wells Fargo Securities United States Emerging Markets North America SRI

JB

Jonathan Breen

Equities editor GlobalCapital Asia